The Ghana Health Service continues to assure that the ongoing malaria vaccine trial is safe.
Speaking to Citi News, the Director of Research and Development Division of the Ghana Health Service, Dr. Abraham Hodgson, said there have not been any complications related to the Malaria vaccine so far.
“Ghanaian scientist were involved in the trial of this vaccine. The Kintampo health research centre; scientists from those places in collaboration with other scientists were those who tried out the vaccine in our populace.”He further assured that “when it came to trial in humans, we were actively involved and we have satisfied our selves; that we like the profile of the vaccine.”
The vaccine, known as RTS, or Mosquirix, developed by GSK formerly GlaxoSmithKline, took more than 30 years to develop.
After initial tests, the vaccine was expanded to cover some 360,000 children in Malawi, Ghana and Kenya to see how well the vaccine works in real-world situations.
The Food and Drugs Authority (FDA) has put in place a monitoring mechanism to keep an eye on the rollout of the malaria vaccine in Ghana alongside Expanded Programme on Immunisation (EPI).
In Ghana, the vaccine was introduced on May 1, 2019 and is being implemented in the Bono, Ahafo, Bono East, Volta, Oti and Central regions, according to service.
The FDA in a statement said these monitoring measures are to ensure that “any adverse events following [the] immunisation are promptly identified and reported to the FDA through its established safety monitoring system.”
The post No complication recorded from malaria vaccination – Health Service appeared first on Citi Newsroom.
Read Full Story
Facebook
Twitter
Pinterest
Instagram
Google+
YouTube
LinkedIn
RSS